Last checked at 3 May 2018 07:00
3 May 2018
IXICO plc
("IXICO" or the "Company")
Notice of Interim Results
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, will announce its interim results for the six months ending 31 March 2018 on Wednesday 23 May 2018.
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
|
|
Shore Capital (Nomad and Broker) Edward Mansfield/Anita Ghanekar | Tel: +44 20 7408 4090 |
|
|
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan | Tel: +44 20 3727 1000 |
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com